Epstein-Barr virus (EBV) is an oncogenic human herpesvirus that persistently infects 195% of adults worldwide. EBV is associated with the infectious mononucleosis syndrome, malignant lymphomas, and nasopharyngeal carcinoma. Oral hairy leukoplakia (HLP) is an EBVassociated disease [1] that is especially common in HIVinfected individuals [2, 3] . The histopathology of HLP includes epithelial hyperparakeratosis, acanthosis with balloon cells in the spinous layer, and a paucity of inflammation [4] . Fungal superinfection is also frequently
observed [1, 2] . Demonstration of EBV in the lesion is required for a definitive diagnosis of HLP [5] .
HLP is characterized by productive EBV replication in oral squamous epithelial cells [1] . HLP resolves with treatment that inhibits EBV replication, suggesting that replication is necessary for pathogenesis of HLP [6] . EBV replication also occurs in normal oral epithelium, suggesting that replication alone is insufficient for HLP pathogenesis [7] . HLP also occurs in immunosuppressed patients [8, 9] and, rarely, in healthy individuals [10] [11] [12] , suggesting that neither HIV infection nor systemic immunodeficiency is required for HLP pathogenesis.
HIV-associated HLP is characterized by a marked reduction in oral Langerhans cell counts, compared with the number of cells in uninvolved oral epithelium from the same subject or from HIV-infected control subjects [13] [14] [15] [16] . Langerhans cells are migratory, dendritic antigen-presenting cells that normally reside in basal and suprabasal epithelium. HIV infects and replicates in oral Langerhans cells [14, 16, 17] , resulting in either their dysfunction [18, 19] or their frank loss from the oral epithelium [20] . Thus, it has been hy-pothesized that HIV-induced loss of oral Langerhans cells may permit the epithelial EBV infection and expression that ultimately leads to the development of the HLP lesion [14] [15] [16] .
This prospective study tested the alternative hypothesis that productive EBV replication in oral epithelium is responsible for the decreased oral Langerhans cell counts observed in HLP. Sixteen HIV-infected subjects, some with HLP and some without HLP (control subjects), were treated with valacyclovir to inhibit productive EBV replication, and the oral Langerhans cells were counted in oral epithelial surgical biopsy specimens obtained before, during, and after treatment. The data demonstrated a correlation between decreased oral Langerhans cell counts and productive EBV replication and supported our hypothesis that EBV is primarily responsible for the decreased oral Langerhans cell counts in HLP.
SUBJECTS, MATERIALS, AND METHODS
Subjects, study design, and biopsies. Informed consent was obtained from all research subjects participating in this study. The human-experimentation guidelines of each participating institution were followed in the conduct of this research. Sixteen HIV-infected men were enrolled. Data on age, ethnicity, CD4 cell count, and antiretroviral medications were obtained. HIV load data were available for less than one-half of the subjects and could not be meaningfully analyzed for this study. A surgical biopsy specimen of the lateral side of the tongue and/or another HLP site was obtained from each subject. Each subject was treated with valacyclovir (1000 mg orally, every 8 h for 28 days). At the end of the treatment period and while the subject was still receiving valacyclovir, a second surgical biopsy specimen was obtained from the same site(s) as the first biopsy or from the site of any visible persistent lesion. Treatment with valacyclovir was discontinued, and a third surgical biopsy specimen was obtained 28-42 days later from the same site(s) as the first and second biopsies. Biopsy specimens were bisected: one half was immediately frozen and stored at Ϫ80ЊC, and the other half was immediately fixed in formalin and paraffinembedded. Two additional HLP specimens with EBV replication obtained from HIV-seronegative individuals [10] were provided by Dr. Francina Lozada-Nur (School of Dentistry, University of California, San Francisco).
Histopathologic interpretation.
Five-micrometer tissue sections were placed on silane-coated glass slides and stained with hematoxylin-eosin. Specimens were classified by an oral and maxillofacial pathologist as consistent with HLP if they had hyperparakeratosis, acanthosis, and balloon cells [4, 21] . A definitive diagnosis of HLP was made only after subsequent demonstration, by use of molecular studies, of productive EBV replication [5] . Periodic acid-Schiff staining was performed for the detection of fungal pseudohyphae.
Immunohistochemical staining for CD1a antigen and quantification of oral Langerhans cells. Although oral Langerhans cells have been identified in vivo by expression of a variety of different markers-including CD1a, HLA-DR, HLA-DQ, and CD36 [13] [14] [15] [16] -the CD1a cell membrane glycoprotein antigen is the most sensitive and specific marker of oral Langerhans cells [22] [23] [24] . Five-micrometer tissue sections were placed on silane-coated glass slides, deparaffinized, washed with Tris-buffered saline, pretreated with citrate buffer, and steamheated for 20 min. Sections were stained with mouse IgG1 monoclonal antibody clone O10 [24] (Beckman Coulter-Immunotech) and counterstained with hematoxylin. Two investigators blinded to the histopathologic diagnosis and the EBV replication status concurrently counted the CD1a-positive cells in 3 distinct, nonoverlapping, 200ϫ magnification microscopic fields of squamous epithelium. Quantitative results for each specimen were reported as the mean number of oral Langerhans cells per high-power field.
Immunohistochemistry for EBV early antigen-diffuse (EA-D). Five-micrometer tissue sections were placed on silanecoated glass slides, deparaffinized, washed with Tris-buffered saline, pretreated with citrate buffer, and steam-heated for 20 min. Sections were stained with mouse monoclonal antibody to the EBV EA-D protein (NovoCastra) and counterstained with hematoxylin.
Extraction of nucleic acids from tissue specimens. Frozen specimens were pulverized in liquid nitrogen by use of a Mikrodismembrator U shaking ball mill (B. Braun Biotech). Nucleic acids were extracted from the tissue either by dissolution in guanidine isothiocyanate and centrifugation on a cesium chloride step gradient, as described elsewhere [25] , or by dissolution in TRIzol Reagent (GibcoBRL Life Technologies-Invitrogen), according to the manufacturer's instructions.
EBV termini structure analysis. Five micrograms of DNA from each specimen was digested with BamHI, blotted, and hybridized to a 32 P-labeled RNA probe synthesized from the cloned XhoI 1.9-kb EBV genome fragment, as described elsewhere [25, 26] . Linear EBV termini were identified by a ladder array of bands differing in size by an interval of ∼500-700 bp.
EBV replicative gene transcription analysis. Each RNA specimen was analyzed by use of reverse transcription and nested polymerase chain reaction amplification using primers specific for the transcripts of 5 replicative EBV genes: BZLF1, BHRF1 expressed from the H promoter (BHRF1-Hp), BSLF2-BMLF1 (SM), BLLF1b (gp220), and BKRF1 expressed from the F promoter (EBNA-1-Fp), as described elsewhere [6] .
Molecular definition of productive EBV replication. Primary criteria for classifying a specimen as having evidence of EBV replication required transcription of BZLF1, BHRF1-Hp, SM, and gp220 [6] . Alternate criteria for classifying a specimen as having evidence of EBV replication required transcription of BZLF1 and BHRF1-Hp, plus transcription of either SM or gp220, plus at least 1 of the following criteria: transcription of EBNA-1-Fp, linear EBV termini by blot hybridization, or expression of EA-D by immunohistochemical staining [6] . Specimens not meeting the primary or alternate criteria were classified as not having evidence of EBV replication [6] . Statistical data analysis. All statistical calculations were performed by use of SPSS for Windows software (version 10.0.7; SPSS). Pearson's correlation was used for analyzing the relationship between oral Langerhans cell counts and subject age and CD4 cell count. Analysis of variance was used for analyzing the relationship between oral Langerhans cell counts and subject ethnicity and receipt of highly active antiretroviral therapy (HAART). Relationships between oral Langerhans cell counts and fungal superinfection, tissue histopathologic analysis, and EBV replication were determined by use of Fisher's exact test and the t test. All analyses were 2-tailed; was P ! .050 considered to be statistically significant. For analysis of oral Langerhans cell counts by EBV treatment-response category group, mean values and 95% confidence intervals were calculated and plotted on a line chart. Statistically significant differences between mean values of different comparator groups were defined by nonoverlapping 95% confidence intervals on the line chart.
RESULTS

Biological correlates of decreased oral Langerhans cell counts.
The sixteen men in this study were ethnically diverse (38% were white, 31% were African American, 19% were Hispanic, and 12% were Native American). Ages ranged from 29 to 59 years (mean, 40 years; median, 38.5 years), and CD4 cell counts ranged from 0 to 894 cells/mL of blood (mean, 226 cells/mL; median, 235 cells/mL). Twelve subjects (75%) were receiving HAART. Before treatment with valacyclovir, 11 subjects had lingual HLP (1 of these subjects also had HLP separately involving the buccal mucosa), and 1 subject had EBV Figure 1 . Changes in oral Langerhans cell counts in response to treatment with valacyclovir. Graph depicts the changes in mean oral Langerhans cell counts before, during, and after treatment with valacyclovir, stratified by the Epstein-Barr virus (EBV) response to treatment with valacyclovir. Nonoverlapping 95% confidence intervals (vertical bars on the data points) represent statistically significant differences in mean oral Langerhans cell counts between the comparator groups. Circles with dots, EBV responserelapse; black circles, no EBV response; black triangles, sustained EBV response; squares, EBV replication-negative control.
replication in normal tongue epithelium. Four subjects lacked both HLP and lingual EBV replication and thus were considered to be control subjects (table 1) .
Among specimens obtained before treatment with valacyclovir, there was no correlation between oral Langerhans cell counts and each of 4 variables: age (P p .942), ethnicity (P p .942), CD4 cell count (P p .585), and receipt of HAART (P p .103). In contrast to the results of a previous study [15] , there was no difference in the prevalence of fungal superinfection when comparing HLP with non-HLP epithelium (P p .751), and there was no correlation of fungal superinfection with decreased oral Langerhans cell counts ( ). These P p .141 results suggest that oral Langerhans cell counts are not significantly influenced by age, ethnicity, CD4 cell count, receipt of HAART, or fungal superinfection.
Among all specimens, decreased oral Langerhans cell counts correlated with both HLP histopathology ( ) (table 2) P р .0001 and productive EBV replication ( ) (table 2) . Because P р .0001 the definition of HLP requires EBV replication [5] and because epithelial EBV replication may occur in the absence of HLP histopathology [7] , we analyzed oral Langerhans cell counts with HLP histopathology and EBV replication status concurrently. In cases of EBV replication, HLP histopathology correlated with decreased oral Langerhans cell counts ( ) P p .028 (table 2) . In cases of non-HLP histopathology, oral Langerhans cell counts did not correlated with EBV replication ( ) P p .491 (table 2) , although the number of cases in which EBV replication occurred in non-HLP tissues may have been too small ( ) to detect a statistically significant difference. These n p 3 results confirm the original correlation between decreased oral Langerhans cell counts and HLP [15] and identify EBV replication as a possible etiologic factor.
Changes in oral Langerhans cell counts in response to treatment with valacyclovir. Each research subject was treated with valacyclovir to inhibit EBV replication in oral tissues. Each series of 3 biopsy specimens obtained from the same subject was categorized by the cumulative EBV response to treatment with valacyclovir (table 1) . Mean oral Langerhans cell counts in specimens obtained before, during, and after treatment with valacyclovir were calculated and plotted on a graph for each EBV treatment response category group (figure 1). Before treatment, oral Langerhans cell counts were significantly higher for the EBV replication-negative control group (figures 1 and 2A) , compared with the other 3 groups with EBV replication (figures 1 and 2B).
During treatment with valacyclovir, significant increases in oral Langerhans cell counts were achieved in both the sustained EBV response group and the EBV response-relapse group, with oral Langerhans cell counts increasing into the same range as that for the EBV replication-negative control group (figures 1 and 2C). This result suggests that inhibition of EBV replication increases oral Langerhans cell counts to normal control levels within 4 weeks. Oral Langerhans cell counts in the group with no EBV response did not increase during treatment, suggesting that the increases seen in the other 2 groups were specifically due to inhibition of EBV replication and not to a stimulatory effect of valacyclovir on oral Langerhans cells.
After treatment, oral Langerhans cell counts in the group with sustained EBV response (where EBV replication did not return) decreased only slightly and remained in the same range as that for the EBV replication-negative control group (figure 1). However, as EBV replication returned in the EBV responserelapse group, oral Langerhans cell counts decreased to pretreatment levels and were significantly lower than those of the 2 groups without EBV replication after treatment (figures 1 and Figure 2 . Oral Langerhans cells detected in lingual basal and suprabasal epithelium by staining (brown) for CD1a antigen, in specimens from HIVinfected subjects (original magnification, 400ϫ for all photomicrographs). A, Biopsy specimen from a control subject with neither hairy leukoplakia (HLP) nor Epstein-Barr virus (EBV) replication, demonstrating numerous oral Langerhans cells. B, Biopsy specimen from subject 2, who had HLP and EBV replication before treatment with valacyclovir, demonstrating few oral Langerhans cells. C, Biopsy specimen from subject 2, after HLP resolution and without EBV replication during treatment with valacyclovir, demonstrating increased oral Langerhans cell counts. D, Biopsy specimen from subject 2, with recurrent HLP and EBV replication after treatment with valacyclovir, demonstrating decreased oral Langerhans cell counts.
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). This observation strengthens the correlation between decreased oral Langerhans cell counts and EBV replication.
Decreased oral Langerhans cell counts in non-HIV-associated HLP. To determine whether the correlation between EBV replication and decreased oral Langerhans cell counts is independent of HIV infection, we examined HLP specimens with evidence of EBV replication obtained from 2 HIV-seronegative and otherwise healthy individuals [10] . CD1a staining revealed !1 oral Langerhans cell/high-power field for each of these 2 HLP specimens, demonstrating that decreased oral Langerhans cell counts in HLP occur in the absence of HIV infection and systemic immunodeficiency. This result supports the hypothesis that EBV replication is primarily responsible for the decreased oral Langerhans cell counts in HLP.
DISCUSSION
The present study is the first to examine the relationship in vivo between EBV replication and oral Langerhans cell counts. Three lines of evidence support the hypothesis that productive EBV replication in HLP results in decreased oral Langerhans cell counts. First, EBV replication in HLP is statistically correlated with decreased oral Langerhans cell counts. Second, the effect of EBV replication on oral Langerhans cell counts is reversible: inhibition of EBV replication increases oral Langerhans cell counts, and the subsequent return of EBV replication decreases oral Langerhans cell counts. Third, the association between EBV replication in HLP and decreased oral Langerhans cell counts in HLP occurs in the absence of HIV infection.
Although these data do not exclude a role for HIV infection in decreasing oral Langerhans cell counts [14] [15] [16] , they do indicate that EBV replication in HLP has a detrimental effect on oral Langerhans cell counts. Although examples from individual subjects may not fully conform to the conclusions of the present study, the remarkable statistical significance of these data, in total, supersedes individual variation and suggests that the effect of EBV replication on oral Langerhans cell counts is real. Unfortunately, because of the small number of specimens with EBV replication in non-HLP epithelium, these data could not demonstrate that the effect of EBV replication on oral Langerhans cell counts occurs independently of the HLP phenotype.
There are 2 nonmutually exclusive mechanistic hypotheses that can be proposed to explain this effect. The first hypothesis is the "Langerhans cell death" hypothesis, stated as the following: "EBV infection and productive replication within Langerhans cells kills them to reduce their numbers in HLP." It is uncertain whether EBV virions produced in HLP could directly infect existing oral Langerhans cells. Langerhans cells do not express CD21, the classic EBV cell-surface receptor, and EBV has not been detected in Langerhans cell tumors [27] . However, it is possible that EBV replicating in upper-layer oral epithelial cells might infect adjacent Langerhans cell dendrites through direct cell-to-cell spread [28] . EBV replication in oral Langerhans cells could potentially kill them, perhaps through an apoptotic mechanism similar to that which occurs in B lymphocytes [29, 30] . Alternatively, EBV may infect Langerhans precursor cells in the peripheral blood [31] [32] [33] . As the EBV-infected precursors immigrate into oral epithelium and differentiate into oral Langerhans cells, latent EBV infection could reactivate to productive EBV replication, killing the oral Langerhans cells and serving as a source of EBV to the oral epithelium. The second hypothesis is the "Langerhans cell emigrationimmigration" hypothesis, stated as the following: "Langerhans cells emigrate from HLP in response to EBV antigens, and new Langerhans cell immigrants fail to repopulate HLP." Replicative EBV antigens could saturate existing oral Langerhans cells, causing them to emigrate from the HLP epithelium to submucosal and lymphoid tissues. Persistent production of EBV antigen could stimulate the immediate maturation and emigration of new oral Langerhans cell immigrants. Evidence of activated oral Langerhans cell-T lymphocyte conjugates in the submucosa of HLP [16] supports this hypothesis.
In addition, EBV may inhibit immigration of new oral Langerhans cells into HLP. The basal epithelium of HLP occasionally contains incompletely differentiated cells expressing monocyticdendritic antigens CD11c and CD14, but not oral Langerhans cell antigens CD1a and HLA-DR [13, 14] . The EBV BCRF1 gene, a functional homologue of interleukin (IL)-10 [34, 35] , is expressed during EBV replication in HLP [36, 37] and could down-regulate expression of proinflammatory cytokines and chemokines important in Langerhans cell differentiation from CD14 + monocytes [22, 23, 38, 39] . EBV also inhibits differentiation of dendritic cells and induces apoptosis in CD14 + monocytes treated in vitro with GM-CSF and IL-4 [40] . This effect is mediated through interaction of the gp25-gp42-gp85 virion glycoprotein complex with the monocyte cell surface and does not require EBV infection of the monocytes [40] . Thus, EBV replication may inhibit differentiation and immigration of new oral Langerhans cells into HLP through the expression of virally encoded immunomodulators.
Elimination of oral Langerhans cells by EBV replication may represent an intrinsic viral mechanism for evasion of the adaptive immune response. The absence of oral Langerhans cells and the corresponding lack of antigen presentation could create a state of immunologic ignorance and/or tolerance of oral EBV infection [41] . Failure to initiate a local, EBV-specific, T lymphocyte immune response would permit EBV replication to persist in the oral epithelium. Oral EBV replication can persist for many months, as demonstrated in HLP [42] , in individuals after resolution of infectious mononucleosis [43] and in otherwise healthy carriers of EBV [44] . Persistent oral EBV replication may be part of the natural biology of EBV, serving as an efficient means of EBV transmission to new hosts.
Decreased oral Langerhans cell counts may facilitate the pathogenesis of HLP as an exaggerated manifestation of persistent EBV replication, coupled with additional unidentified pathogenic cofactors [7] . Decreased oral Langerhans cell counts may also permit oral epithelial superinfection. Although the data on fungal superinfection from the present study failed to demonstrate a correlation, it is still plausible that the oral immunologic ignorance and/or tolerance induced by EBV replication may extend to other pathogenic microorganisms.
In summary, the present study has demonstrated an in vivo EBV replication effect of decreasing oral Langerhans cell counts in HLP. This effect likely represents a novel viral strategy of immune evasion that may have evolved to facilitate persistent oral epithelial EBV infection and that may contribute to the pathogenesis of HLP. The mechanism of this effect remains to be determined.
